v3.25.4

SEGMENT INFORMATION (Tables)

12 Months Ended

Oct. 31, 2025

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

 SCHEDULE OF SEGMENT INFORMATION

		For the Years Ended October 31,
		2025																2024
		Cancer Vaccines				CAR-T Therapies				Other				Total				Cancer Vaccines				CAR-T Therapies				Other				Total
Revenues		$	-			$	-			$	-			$	-			$	-			$	-			$	-			$	-
Research & development expenses			3,121				1,950				-				5,071				3,748				2,648				-				6,396
General & administrative expenses			4,137				2,439				54				6,630				4,291				3,084				60				7,435
Total operating expenses			7,258				4,389				54				11,701				8,039				5,732				60				13,831
Loss from operations			(7,394	)			(4,453	)			(54	)			(11,701	)			(8,039	)			(5,732	)			(60	)			(13,831	)
Interest income			417				252				4				673				651				476				6				1,133
Net loss		$	(6,841	)		$	(4,137	)		$	(50	)		$	(11,028	)		$	(7,388	)		$	(5,256	)		$	(54	)		$	(12,698	)
Total operating expenses		$	7,258			$	4,389			$	54			$	11,701			$	8,039			$	5,732			$	60			$	13,831
Less non-cash stock-based compensation			(2,365	)			(1,435	)			(10	)			(3,810	)			(2,804	)			(1,966	)			(12	)			(4,782	)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)		$	4,893			$	2,954			$	44			$	7,891			$	5,235			$	3,766			$	48			$	9,049

		October 31,
		2025				2024
Total assets:
Cancer Vaccines		$	9,604			$	12,917
CAR-T Therapeutics			6,347				8,535
Other			129				139
Total		$	16,080			$	21,591
Total assets		$	16,080			$	21,591

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration